Marinus Pharmaceuticals Receives Positive Committee For Medicinal Products For Human Use Opinion For ZTALMY For The Adjunctive Treatment Of Seizures Associated With CDKL5 Deficiency Disorder
Portfolio Pulse from Happy Mohamed
Marinus Pharmaceuticals has received a positive opinion from the European Medicines Agency's CHMP for ZTALMY, an adjunctive treatment for seizures associated with CDKL5 deficiency disorder. The European Commission is expected to make a decision within 67 days.
May 26, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharmaceuticals received a positive CHMP opinion for ZTALMY, potentially leading to approval in the EU for treating seizures associated with CDKL5 deficiency disorder.
The positive CHMP opinion for ZTALMY is a significant step towards approval in the EU, which would expand the market for Marinus Pharmaceuticals' product. This could lead to increased revenues and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100